Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions
TVTX Stock Forecast
Travere Therapeutics stock forecast is as follows: an average price target of $21.75 (represents a 29.00% upside from TVTX’s last price of $16.86) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.
TVTX Price Target
The average price target for Travere Therapeutics (TVTX) is $21.75 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $33.00 to $12.00. This represents a potential 29.00% upside from TVTX's last price of $16.86.
TVTX Analyst Ratings
According to 15 Wall Street analysts, Travere Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TVTX stock is 0 'Strong Buy' (0.00%), 12 'Buy' (80.00%), 3 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Travere Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Liisa Bayko | Evercore ISI | $33.00 | $17.50 | 88.57% | 95.73% |
| Oct 21, 2024 | Mohit Bansal | Wells Fargo | $27.00 | $17.87 | 51.09% | 60.14% |
| Oct 10, 2024 | Liisa Bayko | Evercore ISI | $30.00 | $18.07 | 66.02% | 77.94% |
| Oct 09, 2024 | Jason Zemansky | Bank of America Securities | $20.00 | $15.21 | 31.49% | 18.62% |
| Oct 01, 2024 | Carter Gould | Barclays | $18.00 | $13.99 | 28.66% | 6.76% |
| Sep 27, 2024 | Vamil Divan | Guggenheim | $23.00 | $15.04 | 52.93% | 36.42% |
| Sep 27, 2024 | Ed Arce | H.C. Wainwright | $18.00 | $15.04 | 19.68% | 6.76% |
| Sep 27, 2024 | Greg Harrison | Bank of America Securities | $18.00 | $14.01 | 28.48% | 6.76% |
| Sep 10, 2024 | Ed Nash | Canaccord Genuity | $23.00 | $12.70 | 81.17% | 36.42% |
| Sep 09, 2024 | Vamil Divan | Guggenheim | $12.50 | $6.31 | 98.10% | -25.86% |
| Aug 28, 2024 | Nicole Gabreski | Piper Sandler | $12.00 | $8.96 | 33.93% | -28.83% |
| Aug 02, 2024 | Ed Arce | H.C. Wainwright | $10.00 | $4.62 | 116.45% | -40.69% |
| May 07, 2024 | Ed Nash | Canaccord Genuity | $9.00 | $3.28 | 174.39% | -46.62% |
| Apr 24, 2024 | Ed Arce | H.C. Wainwright | $9.50 | $2.74 | 246.72% | -43.65% |
| Dec 05, 2022 | Wells Fargo | $28.00 | $20.08 | 39.44% | 66.07% |
The latest Travere Therapeutics stock forecast, released on Oct 31, 2024 by Liisa Bayko from Evercore ISI, set a price target of $33.00, which represents a 88.57% increase from the stock price at the time of the forecast ($17.50), and a 95.73% increase from TVTX last price ($16.86).
Travere Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 8 | 14 |
| Avg Price Target | - | $23.38 | $18.79 |
| Last Closing Price | $16.86 | $16.86 | $16.86 |
| Upside/Downside | -100.00% | 38.67% | 11.45% |
In the current month, the average price target of Travere Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Travere Therapeutics's last price of $16.86. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 29, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 21, 2024 | Wells Fargo | Sector Outperform | Sector Outperform | Hold |
| Oct 21, 2024 | Wells Fargo | Buy | Overweight | Upgrade |
| Oct 16, 2024 | Wedbush | Sector Outperform | Sector Outperform | Hold |
| Oct 16, 2024 | Scotiabank | Outperform | Initialise | |
| Oct 10, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Oct 09, 2024 | Wedbush | Outperform | Outperform | Hold |
| Oct 01, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 27, 2024 | Leerink Partners | Market Perform | Downgrade | |
| Sep 27, 2024 | Stephens | Overweight | Overweight | Hold |
| Sep 27, 2024 | Morgan Stanley | Overweight | Upgrade | |
| Sep 27, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 27, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 10, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 09, 2024 | Guggenheim | Buy | Upgrade | |
| Sep 06, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 30, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 28, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 02, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 02, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 02, 2024 | Wedbush | Outperform | Outperform | Hold |
| Aug 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 02, 2024 | Barclays | Overweight | Overweight | Hold |
| May 28, 2024 | William Blair | Market Perform | Market Perform | Hold |
| May 07, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Apr 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 17, 2024 | Wells Fargo | Buy | Buy | Hold |
| Mar 13, 2024 | Wells Fargo | Buy | Buy | Hold |
| Feb 16, 2024 | Wedbush | Buy | Buy | Hold |
| Jan 18, 2024 | Sandler O'Neill | Buy | Buy | Hold |
| Dec 05, 2023 | Citigroup | Buy | Upgrade | |
| Sep 22, 2023 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| Sep 21, 2023 | William Blair | Market Perform | Downgrade | |
| Sep 19, 2023 | Evercore ISI | Outperform | Outperform | Hold |
| Feb 21, 2023 | Piper Sandler | Overweight | Initialise | |
| Feb 21, 2023 | Wedbush | Outperform | Upgrade | |
| Dec 05, 2022 | Wells Fargo | Overweight | Initialise | |
| Oct 14, 2022 | H.C. Wainwright | Buy | Buy | Hold |
Travere Therapeutics's last stock rating was published by Cowen & Co. on Oct 29, 2024. The company gave TVTX a "Buy" rating, the same as its previous rate.
Travere Therapeutics Financial Forecast
Travere Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $37.09M | $59.70M | $56.99M | $55.87M | $53.50M | $54.17M | $48.49M | $57.25M | $68.22M | $54.62M | $47.41M | $50.98M | $51.14M | $48.43M | $47.77M | $46.69M | $44.37M | $44.71M | $39.57M |
| Avg Forecast | $111.48M | $93.17M | $86.41M | $72.20M | $71.06M | $60.87M | $50.40M | $43.46M | $41.69M | $57.33M | $53.56M | $50.61M | $53.01M | $54.12M | $49.63M | $52.19M | $57.80M | $60.93M | $50.33M | $50.09M | $51.66M | $47.84M | $47.59M | $43.43M | $46.02M | $45.29M | $43.01M | $41.41M |
| High Forecast | $148.12M | $123.80M | $114.82M | $100.42M | $83.67M | $60.95M | $50.40M | $43.46M | $44.27M | $131.96M | $71.17M | $67.24M | $70.44M | $54.12M | $49.63M | $52.19M | $57.80M | $60.93M | $50.33M | $50.09M | $51.66M | $47.84M | $47.59M | $43.43M | $46.02M | $45.29M | $43.01M | $41.41M |
| Low Forecast | $85.40M | $71.38M | $66.20M | $50.16M | $64.11M | $60.78M | $50.40M | $43.46M | $39.31M | $15.17M | $41.03M | $38.77M | $40.62M | $54.12M | $49.63M | $52.19M | $57.80M | $60.93M | $50.33M | $50.09M | $51.66M | $47.84M | $47.59M | $43.43M | $46.02M | $45.29M | $43.01M | $41.41M |
| # Analysts | 3 | 3 | 3 | 5 | 10 | 9 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | 1.11% | 1.13% | 1.05% | 0.99% | 1.09% | 0.93% | 0.99% | 1.12% | 1.09% | 0.95% | 0.99% | 1.07% | 1.02% | 1.10% | 1.01% | 0.98% | 1.04% | 0.96% |
Travere Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $41.69M, with a low forecast of $39.31M, and a high forecast of $44.27M. TVTX's average Quarter revenue forecast represents a 12.39% increase compared to the company's last Quarter revenue of $37.09M (Sep 23).
Travere Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 10 | 9 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-89.24M | $-85.69M | $-67.01M | $-65.03M | $-54.86M | $-50.99M | $-49.65M | $-42.15M | $-8.96M | $-25.98M | $-33.57M | $-17.36M | $-6.24M | $-11.23M | $-7.63M | $-11.11M | $-12.09M | $-25.62M | $-20.14M |
| Avg Forecast | $-92.70M | $-77.48M | $-71.86M | $-60.04M | $-59.09M | $-50.62M | $-41.91M | $-51.39M | $-34.67M | $-47.68M | $-44.54M | $-46.72M | $-34.03M | $-36.24M | $-33.24M | $-42.47M | $-38.71M | $-40.81M | $-33.71M | $-21.40M | $-34.60M | $-32.04M | $-31.87M | $-29.08M | $-30.82M | $-30.33M | $-28.80M | $-27.73M |
| High Forecast | $-71.02M | $-59.36M | $-55.05M | $-41.71M | $-53.32M | $-50.55M | $-41.91M | $-41.11M | $-32.69M | $-12.61M | $-34.12M | $-37.38M | $-27.22M | $-36.24M | $-33.24M | $-33.98M | $-38.71M | $-40.81M | $-33.71M | $-17.12M | $-34.60M | $-32.04M | $-31.87M | $-29.08M | $-30.82M | $-30.33M | $-28.80M | $-27.73M |
| Low Forecast | $-123.17M | $-102.95M | $-95.48M | $-83.51M | $-69.58M | $-50.69M | $-41.91M | $-61.67M | $-36.81M | $-109.74M | $-59.18M | $-56.06M | $-40.83M | $-36.24M | $-33.24M | $-50.97M | $-38.71M | $-40.81M | $-33.71M | $-25.68M | $-34.60M | $-32.04M | $-31.87M | $-29.08M | $-30.82M | $-30.33M | $-28.80M | $-27.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.87% | 1.92% | 1.43% | 1.91% | 1.51% | 1.53% | 1.17% | 1.09% | 0.22% | 0.77% | 1.57% | 0.50% | 0.19% | 0.35% | 0.26% | 0.36% | 0.40% | 0.89% | 0.73% |
undefined analysts predict TVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Travere Therapeutics's previous annual EBITDA (undefined) of $NaN.
Travere Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 10 | 9 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $150.74M | $-85.63M | $-86.33M | $-65.82M | $-69.66M | $-67.03M | $-75.97M | $-51.57M | $-35.64M | $-39.01M | $-53.87M | $-121.62M | $-22.55M | $-26.07M | $808.00K | $-30.26M | $-36.49M | $-38.70M | $-40.98M |
| Avg Forecast | $-518.55K | $-19.70M | $-25.02M | $-36.95M | $-49.58M | $-52.04M | $-61.52M | $-59.48M | $-90.04M | $-82.79M | $-84.67M | $-54.07M | $-43.38M | $-73.45M | $-72.76M | $-49.16M | $-57.02M | $-43.53M | $-52.96M | $-27.35M | $-33.33M | $-39.97M | $-35.65M | $-43.56M | $-45.61M | $-58.79M | $-38.86M | $-35.46M |
| High Forecast | $-360.89K | $-13.71M | $-17.41M | $-11.24M | $-39.18M | $-36.22M | $-42.82M | $-47.58M | $-60.26M | $2.77B | $-58.93M | $-43.26M | $-34.71M | $-73.45M | $-72.76M | $-39.33M | $-57.02M | $-43.53M | $-52.96M | $-21.88M | $-33.33M | $-39.97M | $-35.65M | $-43.56M | $-45.61M | $-58.79M | $-38.86M | $-35.46M |
| Low Forecast | $-740.15K | $-28.12M | $-35.71M | $-48.99M | $-61.57M | $-74.28M | $-87.81M | $-71.38M | $-109.89M | $-2.24B | $-120.85M | $-64.89M | $-52.06M | $-73.45M | $-72.76M | $-58.99M | $-57.02M | $-43.53M | $-52.96M | $-32.82M | $-33.33M | $-39.97M | $-35.65M | $-43.56M | $-45.61M | $-58.79M | $-38.86M | $-35.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.82% | 1.01% | 1.60% | 1.52% | 0.95% | 0.92% | 1.55% | 0.90% | 0.82% | 0.74% | 1.97% | 3.65% | 0.56% | 0.73% | -0.02% | 0.66% | 0.62% | 1.00% | 1.16% |
Travere Therapeutics's average Quarter net income forecast for Dec 23 is $-90.04M, with a range of $-109.89M to $-60.26M. TVTX's average Quarter net income forecast represents a -159.73% decrease compared to the company's last Quarter net income of $150.74M (Sep 23).
Travere Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 10 | 9 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $67.80M | $74.04M | $72.25M | $62.92M | $57.52M | $52.98M | $46.79M | $42.08M | $36.06M | $34.97M | $36.78M | $35.74M | $31.95M | $34.97M | $33.14M | $27.53M | $29.78M | $38.97M | $32.67M |
| Avg Forecast | $110.27M | $92.17M | $85.48M | $71.42M | $70.29M | $60.21M | $49.85M | $36.63M | $41.24M | $56.71M | $52.98M | $33.30M | $35.39M | $50.73M | $46.52M | $30.27M | $54.18M | $57.11M | $47.18M | $18.67M | $48.42M | $44.84M | $44.61M | $40.70M | $43.14M | $42.45M | $40.31M | $38.81M |
| High Forecast | $146.52M | $122.46M | $113.58M | $99.33M | $82.77M | $60.29M | $49.85M | $43.96M | $43.79M | $130.53M | $70.40M | $39.96M | $42.47M | $50.73M | $46.52M | $36.33M | $54.18M | $57.11M | $47.18M | $22.41M | $48.42M | $44.84M | $44.61M | $40.70M | $43.14M | $42.45M | $40.31M | $38.81M |
| Low Forecast | $84.48M | $70.61M | $65.49M | $49.61M | $63.42M | $60.13M | $49.85M | $29.31M | $38.88M | $15.00M | $40.59M | $26.64M | $28.31M | $50.73M | $46.52M | $24.22M | $54.18M | $57.11M | $47.18M | $14.94M | $48.42M | $44.84M | $44.61M | $40.70M | $43.14M | $42.45M | $40.31M | $38.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.20% | 1.40% | 2.17% | 1.78% | 1.13% | 1.14% | 1.55% | 0.78% | 0.63% | 0.74% | 1.97% | 0.74% | 0.71% | 0.78% | 0.81% | 0.64% | 0.70% | 0.97% | 0.84% |
Travere Therapeutics's average Quarter SG&A projection for Dec 23 is $41.24M, based on 8 Wall Street analysts, with a range of $38.88M to $43.79M. The forecast indicates a -39.17% fall compared to TVTX last annual SG&A of $67.80M (Sep 23).
Travere Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 10 | 9 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $1.98 | $-0.00 | $-1.27 | $-1.03 | $-1.09 | $-1.05 | $-1.20 | $-0.84 | $-0.59 | $-0.64 | $-0.96 | $-2.37 | $-0.44 | $-0.58 | $0.02 | $-0.70 | $-0.85 | $-0.92 | $-0.99 |
| Avg Forecast | $-0.01 | $-0.25 | $-0.32 | $-0.47 | $-0.64 | $-0.67 | $-0.79 | $-0.96 | $-1.16 | $-1.06 | $-1.09 | $-1.20 | $-1.13 | $-0.95 | $-0.94 | $-0.87 | $-0.74 | $-0.56 | $-0.68 | $-0.52 | $-0.43 | $-0.52 | $-0.46 | $-0.56 | $-0.59 | $-0.76 | $-0.50 | $-0.46 |
| High Forecast | $-0.00 | $-0.18 | $-0.22 | $-0.14 | $-0.50 | $-0.47 | $-0.55 | $-0.67 | $-0.77 | $35.55 | $-0.76 | $-0.84 | $-0.79 | $-0.95 | $-0.94 | $-0.87 | $-0.74 | $-0.56 | $-0.68 | $-0.52 | $-0.43 | $-0.52 | $-0.46 | $-0.56 | $-0.59 | $-0.76 | $-0.50 | $-0.46 |
| Low Forecast | $-0.01 | $-0.36 | $-0.46 | $-0.63 | $-0.79 | $-0.96 | $-1.13 | $-1.37 | $-1.41 | $-28.74 | $-1.55 | $-1.71 | $-1.62 | $-0.95 | $-0.94 | $-0.87 | $-0.74 | $-0.56 | $-0.68 | $-0.52 | $-0.43 | $-0.52 | $-0.46 | $-0.56 | $-0.59 | $-0.76 | $-0.50 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.86% | 0.00% | 1.06% | 0.91% | 1.15% | 1.12% | 1.38% | 1.14% | 1.05% | 0.94% | 1.84% | 5.51% | 0.85% | 1.26% | -0.04% | 1.19% | 1.12% | 1.83% | 2.16% |
According to 8 Wall Street analysts, Travere Therapeutics's projected average Quarter EPS for Dec 23 is $-1.16, with a low estimate of $-1.41 and a high estimate of $-0.77. This represents a -158.47% decrease compared to TVTX previous annual EPS of $1.98 (Sep 23).
Travere Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| ANAB | AnaptysBio | $15.99 | $49.83 | 211.63% | Buy |
| LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| IDYA | IDEAYA Biosciences | $26.33 | $53.33 | 102.54% | Buy |
| COGT | Cogent Biosciences | $8.19 | $16.00 | 95.36% | Buy |
| CYTK | Cytokinetics | $47.78 | $90.00 | 88.36% | Buy |
| RNA | Avidity Biosciences | $32.74 | $59.00 | 80.21% | Buy |
| PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| PTGX | Protagonist Therapeutics | $40.69 | $57.33 | 40.89% | Buy |
| MGTX | MeiraGTx | $6.40 | $9.00 | 40.63% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |
| TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |